Luminex Expects 2013 FDA Clearance for Gastro Pathogen Panel as Q3 Revenues Rise 10 Percent | GenomeWeb

Luminex hopes to see two new screening assays cleared by the US Food and Drug Administration next year that together address a market opportunity of about $200 million. In addition, the firm is continuing to develop a new molecular diagnostics instrument gained through its recent acquisition of GenturaDx that it hopes to debut in 2014.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.